According to the latest market report, the global targeted protein degradation market, valued at US$0.01 billion in 2024, surged to US$0.48 billion in 2025 and is expected to grow at a remarkable CAGR of 35.4% from 2025 to 2035, ultimately reaching US$9.85 billion by 2035.

Market Growth Insights & Trends

The targeted protein degradation market is experiencing exponential growth due to:

• Priority/Fast Track designations granted by regulatory agencies.
• First-in-class approvals expected in the near term.
• Multi-indication expansion for oncology, immunology, and rare diseases.

By 2035, the TPD market will be a multi-billion-dollar sector, shaping the future of drug discovery and precision medicine.

📈 Key Trend Highlights

• Increasing collaborations between biotech and pharma companies for TPD pipeline development.
• Expansion of clinical trials for oncology-focused protein degraders.
• Adoption of AI-driven drug discovery in identifying new degrader targets.

Download PDF Brochure: 

Key Drivers of Market Growth

1. Breakthrough Therapeutic Potential – PROTACs and molecular glues address “undruggable” proteins that traditional small molecules cannot.
2. Regulatory Acceleration – FDA and EMA fast-track designations are expediting approvals.
3. Expanding Clinical Pipeline – More than 100+ TPD candidates are currently in preclinical and clinical stages.
4. Strategic Collaborations – Big pharma companies like Pfizer, Novartis, and Merck are heavily investing in targeted protein degradation partnerships.
5. Rising Oncology Burden – Cancer treatment is expected to be the leading application area for protein degraders.

Challenges & Opportunities

While the market outlook is highly positive, challenges remain:

• Manufacturing complexities of bifunctional degraders (PROTACs).
• Limited biomarker validation for certain targets.
• High R&D costs in developing next-gen degraders.

💡 Opportunities:

• Development of oral bioavailable degraders.
• Leveraging artificial intelligence to accelerate degrader design.
• Expansion into autoimmune and neurodegenerative diseases beyond oncology.

Competitive Landscape

The competitive landscape of the targeted protein degradation market is rapidly evolving. Key players include:

• Arvinas, Inc. – Pioneer in PROTAC technology.
• Nurix Therapeutics – Strong degrader pipeline in oncology.
• C4 Therapeutics – Advancing multiple protein degrader candidates.
• Kymera Therapeutics – Focused on immunology and oncology.
• Pfizer, Novartis, and Merck – Strategic collaborations with biotech innovators.

Request Sample Pages : 

Future Outlook: Targeted Therapies by 2035

Looking ahead, the targeted protein degradation market is set to redefine drug development:

• First FDA approvals for PROTAC-based therapies are anticipated before 2030.
• Expansion of TPD into rare diseases and neurology.
• Greater adoption of AI, machine learning, and computational biology to accelerate degrader discovery.
• Emergence of next-generation molecular glues with broader applications.

By 2035, protein degraders will move from niche innovation to mainstream therapeutic class, reshaping the global precision medicine market.